AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01126203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLT
Description: All eyes will be treated using a commercially available Q-switched Nd:YAG laser (Coherent Selecta 7000, Coherent Inc., Palo Alto , CA, USA) calibrated by the manufacturer. On the day of treatment, IOP will be measured, then one drop of Apraclonidine 1% or Brimonidine 0.2% and pilocarpine 1% or 2% will be instilled. Before the patient is seated at the laser slit-lamp system a proparacaine hydrochloride drop will be instilled in the eye to be treated. A Goldmann goniolens or a Latina SLT or any other goniolens will be placed on the eye to be treated with methyl cellulose 1%. The helium-neon aiming beam is focused onto the pigmented trabecular meshwork. SLT will be performed with approximately 50 applications, a 400um spot size with energies varying from 0.8-1.2 mjoules.
Study NCT01126203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ALT
Description: All eyes will be treated using Ophthalas 532 Eyelite Laser Photocoagulator (Alcon Surgical, Dallas-Fort Worth, Texas, USA. On the day of treatment, IOP will be measured, then on the day of treatment, IOP will be measured, then one drop of Apraclonidine 1% or Brimonidine 0.2% and pilocarpine 1% will be instilled. Before the patient is seated at the laser slit-lamp system a proparacaine hydrochloride drop will be instilled in the eye to be treated. A Goldmann goniolens will be placed on the eye to be treated with methyl cellulose 1%. The aiming beam is focused onto the anterior portion of the pigmented trabecular meshwork. ALT will be performed to the superior or inferior 180 degrees with \~ 50 applications, a 50um spot size with energies varying from 400-700 mW with 0.1 second duration.
Study NCT03338933 — intervention group
Intervention type: BEHAVIORAL
Intervention: magnetic resonance imaging (MRI)
Description: All subjects will undergo a baseline MRI and subjects in both alcohol groups (alcohol use disorder and combined alcohol and nicotine use disorder) will undergo a followup MRI 3 months after baseline.
Study NCT02911792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: SGLT2 inhibitor
Study NCT02911792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral diabetes medicine that helps control blood sugar levels.
Study NCT02911792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide 5 MG
Description: Oral diabetes medicine that helps control blood sugar levels.
Study NCT02816996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand-holding
Description: Subject will have their hand held.
Study NCT02816996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stress Ball
Description: Subject will be given a stress ball to hold.
Study NCT01424124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD001 dose level 1
Description: Tablet, three times daily / 8 weeks
Study NCT01424124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD001 dose level 2
Description: Tablet, three times daily / 8 weeks
Study NCT01424124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Singulair
Description: Tablet, one times daily / 8 weeks
Study NCT01424124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, one times daily / 7 days
Study NCT01778205 — intervention group
Intervention type: OTHER
Intervention: Observational
Study NCT04230330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Nivolumab
Description: 240mg every 2 weeks.
Study NCT04230330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Nivolumab
Description: Initial treatment dose is 240mg every 2 weeks for 4 doses. Dose changes to 360mg every 3 weeks when given with GDP/L-aspa. Maintenance treatment dose is 240mg every 2 weeks.
Study NCT04230330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Gemcitabine
Description: 800mg/m2 on Days 1 and 8 every 21 days
Study NCT04230330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Cisplatin
Description: 20mg/m2 on Day 1 to 4 every 21 days
Study NCT04230330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV/PO Dexamethasone
Description: 10mg on Days 1 to 4 every 21 days
Study NCT04230330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV L-asparaginase
Description: 6000 Units/m2 on Days 2 to 8 every 21 days
Study NCT02906293 — intervention group
Intervention type: OTHER
Intervention: Abdominal acoustic measurement
Description: On Day 1 participants will record their intestinal rate at baseline fasting, pre-small meal, and upon completion of the meal. On Day 2 participants will record their intestinal rate at baseline fasting, pre-large meal, and upon completion of meal.
Study NCT00397787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO
Study NCT02596100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban
Study NCT03755947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib Oral Capsule \[Imbruvica\] Tablets 120 mg. Oral. 420mg/day, day 1 to 28, every 28 days. 3 cycles.
Study NCT03755947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab Injection. Intravenous Solution \[Gazyva\] Parenteral. 1000 mg, day 1 of every cycle, every 28 days. 6 cycles.
Study NCT03755947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax Oral Tablets \[Venclexta\] Tablets 100 mg. Oral. 400 mg/day. Day 1 to 28, every 28 days. 12 cycles.
Study NCT01686477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unfortified Human donor Milk used to make up any shortfall in mother's own milk
Study NCT01686477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fortified Human donor Milk used to make up any shortfall in mother's own milk
Study NCT01686477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preterm Formula used when there is a shortfall in mother's own milk
Study NCT03965091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab will be administered per dose and schedule specified in the arm description.
Study NCT03965091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to fremanezumab will be administered per schedule specified in the arm description.
Study NCT00151515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minoxidil
Description: Topical 5% minoxidil foam, BID, for sixteen weeks
Study NCT02655341 — intervention group
Intervention type: DEVICE
Intervention: Body Composition Monitoring
Description: using Fresenius device; two measurements before and after coronary intervention;
Study NCT02655341 — intervention group
Intervention type: PROCEDURE
Intervention: Coronarography
Description: Preprocedural coronary arteriography is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the left coronary stem, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording.
Study NCT02655341 — intervention group
Intervention type: PROCEDURE
Intervention: Primary Percutaneous Coronary Intervention
Description: An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.
Study NCT02655341 — intervention group
Intervention type: PROCEDURE
Intervention: Renal Angiography
Description: After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. This procedure is performed in the same time with primary PCI
Study NCT04333498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback on DBS Concentrations
Description: The study team will examine the feasibility and acceptability of a feedback system based on DBS concentration amounts.
Study NCT02340325 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acute Application of kynurenic acid cream
Description: Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area. The pouch order will be random, generated by the www.random.org list generator each application. The study team member applying the cream will randomly choose the application sites of different concentrations of the FS2 creams and mark the corresponding cream code name on a separate sheet. This study member will not be evaluating the results and the evaluating study member will be blinded to the randomization. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.
Study NCT02340325 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chronic application of kynurenic acid cream
Description: Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30
Study NCT03950804 — intervention group
Intervention type: DRUG
Intervention: Eculizumab Injection
Description: Patients receive eculizumab as deemed necessary by the primary physician
Study NCT00118287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Given SC or IV
Study NCT00118287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Given SC
Study NCT03594838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HCV viremia testing approaches
Description: Blood draw and HCV viremia testing is done at point of service (Intervention A) Blood draw at point of service and HCV viremia testing at a centralized laboratory (Intervention B)
Study NCT03690544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: Apremilast is an oral small-molecule inhibitor of phosphodiesterase (PDE) 4 that works intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. PDE 4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the dominant PDE in inflammatory cells. PDE4 inhibition elevates intracellular cAMP levels, which in turn down-regulates the inflammatory response by modulating the expression of TNF-alfa, IL-23, IL-17 and other inflammatory cytokines. Cyclic AMP also modulates levels of anti-inflammatory cytokines such as IL-10. Apremilast has immunomodulatory activity and, therefore, has the potential to be effective in the treatment of RAS.
Study NCT00957710 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Errorless learning
Description: Language testing,20 sessions of language therapy, and 2 neuroimaging sessions for participants with progressive aphasia Language testing and 1 imaging session for healthy controls
Study NCT02467816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SmartMeal application
Description: The SmartMeal application is a smartphone application that will allow students to pre-order school meals, receive nutrition information about school meals, and provide feedback about school meals to Student Nutrition Services.
Study NCT02467816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distributed points of sale
Description: To increase points of sale for school meals (outside the cafeteria), school meals will be sold at hot and cold mobile food carts and vending machines throughout the school.
Study NCT02467816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staff wellness curriculum
Description: A wellness curriculum will be implemented that encourages teachers and staff members to eat school meals and promote them to students.
Study NCT04254211 — intervention group
Intervention type: OTHER
Intervention: NLR
Description: neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR)
Study NCT02787291 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ellipse VR ICD and Durata/Optisure lead
Description: Non-diagnostic MRI Scan sequence of head and chest
Study NCT01246167 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Philos
Description: Conservative treatment versus Philos locking plate in 2 part fracture group.~Conservative treatment versus Philos locking plating versus Epoca prosthesis in MFF group.
Study NCT01246167 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epoca
Description: Conservative treatment versus Philos locking plate versus Epoca fracture prosthesis in MFF group
Study NCT01246167 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Conservative control group
Study NCT03231176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varlitinib
Description: oral tablets, twice daily
Study NCT03231176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles
Study NCT00484159 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation of medial branches
Description: Radiofrequency of medial branches that innervate the lumbar facet joints
Study NCT00484159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Description: Diagnostic medial branch block with 0.5% bupivacaine. Blocking the nerves that innervate the facet joints with a long-acting local anesthetic.
Study NCT00484159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Description: Diagnostic medial branch block with 2% lidocaine. Blocking the nerves that innervate the facet joints with a short-acting local anesthetic.
Study NCT00484159 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation
Description: Radiofrequency lumbar facet denervation without a diagnostic block
Study NCT00484159 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation
Description: Radiofrequency lumbar facet denervation only if positive response to 2 diagnostic blocks.
Study NCT00484159 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation
Description: Lumbar facet radiofrequency denervation if positive response to a single diagnostic facet block
Study NCT00484159 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation
Description: Radiofrequency lumbar facet denervation without a diagnostic facet block.
Study NCT00446875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of oral Sucrose
Description: Participants received oral sucrose 2 minutes prior to the combind DTaP, IPV, and Hep B vaccine.
Study NCT00446875 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Administration of oral Placebo
Description: Participants received Placebo 2 minutes prior to the combind DTaP, IPV, and Hep B vaccine.
Study NCT02478788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mixed amphetamine salts-extended release (MAS-XR)
Description: MAS-XR is a psychostimulant medication composed of amphetamine and dextroamphetamine, has been systematically studied in adolescents with ADHD, and is FDA-approved for the treatment of ADHD in adolescents.
Study NCT02478788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pills with no medication in it
Study NCT04155554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide
Description: Switch patients from dolutegravir/lamivudine/abacavir to bictegravir/emtricitabine/tenefovir alafenamide to study neuropsychiatric side effects and neurocognitive function
Study NCT04155554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir/lamivudine/abacavir
Description: Continuing dolutegravir/lamivudine/abacavir to study neuropsychiatric side effects and neurocognitive function
Study NCT04832217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pyrenees´ Beef diet
Description: 24 participants were randomly assigned to a Pyrenees' beef diet, 3 serving per week during of 8 weeks.
Study NCT01176175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone microspheres injectable suspension 50 mg, intramuscular weekly injection for a total of 7 doses.
Study NCT01176175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone microspheres injectable suspension 100 mg, intramuscular weekly injection for a total of 7 doses.
Study NCT01176175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone microspheres injectable suspension 200 mg, intramuscular weekly injection for a total of 7 doses.
Study NCT01176175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone microspheres injectable suspension 300 mg, intramuscular weekly injection for a total of 7 doses.
Study NCT06005376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast rolls consisting of wheat flour with and without a E304i/zinc additive
Description: The participants were provided with two Breakfast rolls (a 40 g) a day during the intervention week. In addition, they were provided with gluten-free foods during the whole trial.
Study NCT06005376 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast rolls consisting of wheat flour with and without a E304i/zinc additive
Description: The participants were provided with two Breakfast rolls (a 40 g) a day during the intervention week. In addition, they were provided with gluten-free foods during the whole trial.
Study NCT01111929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Counseling for LAM+ LNG-EC
Description: They will be provided by the above proper LAM counseling and contraceptive counseling. Additionally, they will be provided by EC pills and advised to use these pills if one of the prerequisites of LAM expires and sexual relation with their husband had occurred before the initiation of another long term contraceptive. Each women in this group will be supplied with one packet containing two 0.75 mg Levonorgestrel EC pills and advised to swallow the two tablets as soon as possible after having sexual intercourse with their husband after the expiry of LAM. They will be informed that they should not use the method after more than 5 days of having intercourse.~They will be also advised not to use EC pills more than once. All women who have used the EC pills need to visit the clinic within few days of use for contraception advice. All the above information will be additionally given to the patient in a small flyer.
Study NCT01111929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Counseling for LAM+ LNG-EC
Description: They will be provided by the above proper LAM counseling and contraceptive counseling. Additionally, they will be provided by EC pills and advised to use these pills if one of the prerequisites of LAM expires and sexual relation with their husband had occurred before the initiation of another long term contraceptive. Each women in this group will be supplied with one packet containing two 0.75 mg Levonorgestrel EC pills and advised to swallow the two tablets as soon as possible after having sexual intercourse with their husband after the expiry of LAM. They will be informed that they should not use the method after more than 5 days of having intercourse.~They will be also advised not to use EC pills more than once. All women who have used the EC pills need to visit the clinic within few days of use for contraception advice. All the above information will be additionally given to the patient in a small flyer.
Study NCT00814333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thrombin-JMI
Description: 5,000 IU, to nasal mucosa via syringe spray applicator
Study NCT00814333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Merocel pack
Description: 8 cm pack, inserted within the affected side between the septum and inferior turbinate via bayonet forceps
Study NCT02850081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Standard of care treatment (one of four):~* Simvastatin (to 40mg without amlodipine)~* Simvastatin (to 20 mg if currently on amlodipine)~* Atorvastatin (to 80mg)~* Rosuvastatin (to 20mg)
Study NCT02850081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: A lipid-lowering agent and for prevention of events associated with cardiovascular disease.~10 mg or 80 mg capsules
Study NCT02850081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo pill will be used for patients that are to maintain their current dose of statins prior to their CEA.
Study NCT03720847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Transdermal Patch 0.1 mg/24 hrs
Description: Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation